Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-10T05:10:09.414Z Has data issue: false hasContentIssue false
  • English
  • Français

Transmitter-replacement Therapy in Alzheimer's Disease Using Intracerebroventricular Infusions of Receptor Agonists

Published online by Cambridge University Press:  18 September 2015

S. Gauthier ,
R. Leblanc ,
R. Quirion ,
G. Carlsson ,
M. Beaulieu ,
R. Bouchard ,
D. Dastoor ,
F. Ervin ,
L. Gauthier  and
M. Gauvin
...Show all authors
S. Gauthier*
Affiliation:
Montreal Neurological Hospital and Institute
R. Leblanc
Affiliation:
Montreal Neurological Hospital and Institute
R. Quirion
Affiliation:
Douglas Hospital Research Centre
G. Carlsson
Affiliation:
Intermedics Infusaid Inc.
M. Beaulieu
Affiliation:
Sandoz Canada Research Department
R. Bouchard
Affiliation:
Hospital de l'Enfant Jesus
D. Dastoor
Affiliation:
Douglas Hospital Research Centre
F. Ervin
Affiliation:
Allen Memorial Institute
L. Gauthier
Affiliation:
School of Physical and Occupational Therapy, McGill University
M. Gauvin
Affiliation:
Montreal Neurological Hospital and Institute
J. Henry
Affiliation:
Allen Memorial Institute
R. Palmour
Affiliation:
Allen Memorial Institute
Y. Robitaille
Affiliation:
Montreal Neurological Hospital and Institute
*
Montreal Neurological Institute, 3801 University Street, Montreal, Quebec, Canada H3A 2B4
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Neurotransmitter replacement therapy in Alzheimer's Disease is currently being attempted using bethanechol chloride (Urecholine) infused intracerebroventricularly with an Infusaid continuous infusion pump. The rationale of this therapy is based on the severe cortical pre-synaptic cholinergic deficit in the presence of relatively normal post-synaptic muscarinic receptor density. Patients are selected on the basis of strict clinical criteria at a functional stage 4 or 5 of Reisberg. A cortical biopsy at the time of pump and catheter implantation confirms the diagnosis by histological and biochemical examination. Pre-operative, post-operative and serial mental status assessments combined with functional ADL assessments monitor changes in behavior. A 6 months double-blind treatment period is done in every patient, who is then free to continue if he has improved on active treatment. This specific study is part of a multi-centre trial. Other therapeutic trials using somatostatin analogs, such as Sandostatin, could then be done. The biological effects of the latter compound are being studied currently in adult Green Vervet monkeys, prior to its use in Alzheimer patients. Furthermore autoradiography of bethanechol and peptides labeled with 14C administered in these animals by intracerebroventricular infusion will allow a better knowledge of their pharmacological site of action.

Type
Clinical and Therapeutic Issues
Information
Canadian Journal of Neurological Sciences , Volume 13 , Issue S4 , November 1986 , pp. 394 - 402
Copyright
Copyright © Canadian Neurological Sciences Federation 1986

References

1.Whitehouse, PJ, Price, DL, Struble, RG, et al. Alzheimer’s disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982; 215: 1237–1239.CrossRefGoogle ScholarPubMed
2.Roberts, GW, Crow, TJ, Polak, JM.Location of neuronal tangles in somatostatin neurones in Alzheimer’s disease. Nature 1985; 314: 92–94.CrossRefGoogle ScholarPubMed
3.Yamamoto, T, Hirano, A.Nucleus raphe dorsalis in Alzheimer’s disease: Neurofibrillary tangles and loss of large neurons. Ann Neurol 1985; 17: 573–577.CrossRefGoogle ScholarPubMed
4.Perry, EK, Tomlinson, BE, Blessed, G, et al. Neuropathological and biochemical observations on the noradrenergic system in Alzheimer’s disease. J Neurol Sci 1981; 51: 279–287.CrossRefGoogle ScholarPubMed
5.De Souza, EB, Whitehouse, PJ, Kuhar, MJ, et al. Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer’s disease. Nature 1986; 319: 593–595.CrossRefGoogle ScholarPubMed
6.Etienne, P, Gauthier, S, Johnson, G, et al. Clinical effects of choline in Alzheimer’s disease. Lancet 1978; 1: 508.CrossRefGoogle ScholarPubMed
7.Etienne, P, Dastoor, D, Gauthier, S, et al. Alzheimer disease: Lack of effect of lecithin treatment for 3 months. Neurology 1981; 31: 1552–1554.CrossRefGoogle ScholarPubMed
8.Caltagirone, C, Gainotti, G, Masullo, C.Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer’s presenile dementia. Int J Neurosci 1982; 16: 247–249.CrossRefGoogle ScholarPubMed
9.Davous, P, Lamour, Y.Bethanechol decreases reaction time in senile dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1985; 48: 1297–1299.CrossRefGoogle ScholarPubMed
10.Harbaugh, RE, Roberts, DW, Coombs, DW, et al. Preliminary report: Intracranial cholinergic drug infusion in patients with Alzheimer’s disease. Neurosurgery 1984; 15: 514–518.CrossRefGoogle ScholarPubMed
11.McKhann, G, Drachman, D, Folstein, M, et al. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–944.CrossRefGoogle ScholarPubMed
12.Folstein, MF, Folstein, SE, McHugh, PR.“Mini-Mental State” A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12: 189–198.CrossRefGoogle ScholarPubMed
13.Reisberg, B, Ferris, SH, de Leon, MJ, et al. The global deterioration scale (GDS): An instrument for the assessment of primary degenerative dementia. Am J Psychiat 1982; 139: 1136–1139.Google Scholar
14.Lawton, MP, Brody, EM.Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179–186.CrossRefGoogle ScholarPubMed
15.Linn, MW, Linn, BS.The rapid disability rating scale -11. J Amer Ger Soc 1982; 30: 378–382.CrossRefGoogle Scholar
16.Gauthier, S, Robitaille, Y, Quirion, R, et al. Antemortem laboratory diagnosis of Alzheimer’s disease. Prog Neuro-Psychopharmacol and Biol Psychiat 1986; 10: (in press).CrossRefGoogle ScholarPubMed
17.Cosgrove, GR, Leblanc, R, Meagher-Villemure, K, et al. Cerebral amyloid angiopathy. Neurology 1985; 35: 625–631.CrossRefGoogle ScholarPubMed
18.Ball, MJ.Neuronalloss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. Acta Neuropath 1977; 37: 111–118.Google Scholar
19.Neary, D, Snowden, JS, Mann, DMA, et al. Alzheimer’s disease: a correlative study. J Neurol Neurosurg Psychiatry 1986; 49: 229–237.CrossRefGoogle ScholarPubMed
20.Friedland, RP, Budinger, TF, Brant-Zawadzki, M, et al. The diagnosis of Alzheimer-type dementia. A preliminary comparison of positron emission tomography and proton magnetic resonance. JAMA 1984; 252: 2750–2752.CrossRefGoogle ScholarPubMed
21.Uhi, GR, Tran, V, Snyder, SH, et al. Somastostatin receptors: Distribution in rat central nervous system and human frontal cortex. J Comp Neurol 1985; 240: 288–304.Google Scholar
22.Wood, PL, Etienne, P, Lai, S, et al. Reduced lumbar CSF somatostatin levels in Alzheimer’s disease. Life Sci 1982; 31: 2073–2079.CrossRefGoogle ScholarPubMed
23.Davies, P, Katzman, R, Terry, RD.Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 1980; 288; 279–280.CrossRefGoogle Scholar
24.Beal, MF, Mazurek, MF, Tran, VT, et al. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer’s disease. Science 1985; 229: 289–291.CrossRefGoogle ScholarPubMed
25.Beal, MF, Uhl, G, Mazurek, MF, et al. Somatostatin: Alterations in the central nervous system in neurological diseases. In: Martin, JB, Barchas, JD, eds. Neuropeptides in Neurologic and Psychiatric Disease. New York: Raven Press, 1986: 215–257.Google ScholarPubMed
26.Tamminga, CA, Tanimoto, K, Foster, NL, et al. Alzheimer’s disease: Somatostatin loss in area of maximal fluorodeoxyglucose reduction. Neurology 1985; 35 (Suppl 1): 183.Google Scholar
27.Cutler, NR, Haxby, JV, May, C, et al. L-363,586, a somatostatin analog: An assessment of memory function in Alzheimer’s disease. Neurology 1985; 35 (Suppl 1): 265.Google Scholar
28.Meynadier, J, Chrubasik, J, Dubar, M, et al. Intrathecal somatostatin in terminally ill patients. A report of two cases. Pain 1985; 23: 9–12.CrossRefGoogle ScholarPubMed